Halozyme Announces Takeda Receives FDA Approval for HYQVIA® Co-formulated with ENHANZE® as Maintenance Therapy in Adults with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

/PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that Takeda received U.S. Food and Drug Administration (FDA) approval...

Related Keywords

San Diego ,California ,United States ,Samantha Gaspar ,Eli Lilly ,Helen Torley ,Prnewswire Halozyme Therapeutics Inc ,Bristol Myers Squibb ,Exchange Commission ,Corporate Communications ,Acumen Pharmaceuticals ,Teva Pharmaceuticals ,Halozyme Therapeutics Inc ,Linkedin ,Drug Administration ,Idorsia Pharmaceuticals ,Twitter ,Nasdaq ,Pfizer ,Horizon Therapeutics ,Viiv Healthcare ,Chugai Pharmaceutical ,Annual Report ,Quarterly Reports ,Investor Relations ,Halozyme Therapeutics ,Nc ,